Who are DHEA and Acolbifene's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): teriparatide and raloxifene, Estradiol+MPA, Estrogen vaginal cream, Levonorgestrel/Ethinyl Estradiol, Mirabegron with vaginal estrogen cream, Clomiphene citrate and Estradiol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dhea-and-acolbifene.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DHEA and Acolbifene — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DHEA and Acolbifene (DHEA and Acolbifene) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM) combination. Area: Women's Health / Endocrinology.

phase 3 Selective estrogen receptor modulator (SERM) combination Estrogen receptor alpha and beta Women's Health / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

DHEA and Acolbifene (DHEA and Acolbifene) — EndoCeutics Inc.. DHEA and acolbifene work together as a selective estrogen receptor modulator (SERM) combination to provide estrogen-like benefits in bone and vaginal tissue while minimizing systemic estrogen exposure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DHEA and Acolbifene TARGET	DHEA and Acolbifene	EndoCeutics Inc.	phase 3	Selective estrogen receptor modulator (SERM) combination	Estrogen receptor alpha and beta
teriparatide and raloxifene	teriparatide and raloxifene	Medical University of Vienna	marketed	Combination therapy: PTH analog and selective estrogen receptor modulator (SERM)	PTH1 receptor (teriparatide); estrogen receptor alpha and beta (raloxifene)
Estradiol+MPA	Estradiol+MPA	Brigham and Women's Hospital	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor
Estrogen vaginal cream	Estrogen vaginal cream	The University of Texas Health Science Center, Houston	marketed	Estrogen replacement therapy (topical)	Estrogen receptor alpha and beta
Levonorgestrel/Ethinyl Estradiol	Levonorgestrel/Ethinyl Estradiol	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor alpha and beta
Mirabegron with vaginal estrogen cream	Mirabegron with vaginal estrogen cream	Mackay Memorial Hospital	marketed	Beta-3 adrenergic agonist (mirabegron) + topical estrogen (vaginal cream)	Beta-3 adrenergic receptor (mirabegron); estrogen receptor alpha and beta (vaginal estrogen)
Clomiphene citrate and Estradiol	Clomiphene citrate and Estradiol	Maher elesawi kamel elesawi	marketed	Selective estrogen receptor modulator (SERM) combined with estrogen replacement	Estrogen receptor alpha and beta

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor modulator (SERM) combination class)

EndoCeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DHEA and Acolbifene — Competitive Intelligence Brief. https://druglandscape.com/ci/dhea-and-acolbifene. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing